CD44 has proven to have prognostic and therapeutic potential in several cancer studies13–17 and since CD44 is known to be highly expressed in GC18, we here aimed to explore the role of AF1q in GC’s molecular landscape and clinical implications arising that might elicit promising avenues for screening, prognosis estimation as well as therapy. This evidence concerns the gene CD44 and gastric cancer.